UK markets closed

Infinity Pharmaceuticals, Inc. (INFI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.6400-0.0100 (-1.54%)
At close: 04:00PM EST
0.6450 +0.00 (+0.78%)
After hours: 07:10PM EST

Infinity Pharmaceuticals, Inc.

1100 Massachusetts Avenue
Floor 4
Cambridge, MA 02138
United States
617 453 1000

Full-time employees

Key executives

NameTitlePayExercisedYear born
Ms. Adelene Q. PerkinsChairman & CEO1.15MN/A1960
Dr. Stephane Peluso Ph.D.Chief Scientific Officer577.63kN/A1971
Dr. Robert Ilaria Jr., M.D.Chief Medical Officer643.54kN/A1961
Dr. Lawrence E. Bloch J.D., M.D.Pres & TreasurerN/AN/A1966
Ms. Melissa HackelVP of Fin.N/AN/AN/A
Mr. Seth A. Tasker J.D.Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec.N/AN/A1979
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Infinity Pharmaceuticals, Inc.’s ISS governance QualityScore as of 28 January 2023 is 5. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.